Drugs that contain Cilastatin Sodium; Imipenem; Relebactam
1. Drug name - RECARBRIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Nov, 2029
(7 years from now) | |
| CN102827067A | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
| CN102827067B | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
| CN101918407A | MSD MERCK CO | Beta-1Actamase Inhibitors |
Jan, 2029
(6 years from now) | |
| CN101918407B | MSD MERCK CO | Beta-Lactam Enzyme Inhibitor |
Jan, 2029
(6 years from now) | |
| IN201003977P4 | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
| IN293446B | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
| EP2231667A2 | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
| EP2666774A1 | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
| EP2231667B1 | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
| EP2666774B1 | MSD MERCK CO | Beta-Lactamase Inhibitors |
Jan, 2029
(6 years from now) | |
Treatment: NA
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL | POWDER;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.